» Articles » PMID: 23153566

The Role of Maternal-fetal Cholesterol Transport in Early Fetal Life: Current Insights

Overview
Journal Biol Reprod
Date 2012 Nov 17
PMID 23153566
Citations 53
Authors
Affiliations
Soon will be listed here.
Abstract

The importance of maternal cholesterol as an exogenous cholesterol source for the growing embryo was first reported in studies of Smith-Lemli-Opitz syndrome. Although most of the fetus's cholesterol is synthesized by the fetus itself, there is now growing evidence that during the first weeks of life, when most organs develop, the fetus largely depends on maternal cholesterol as its cholesterol source. The maternal-fetal cholesterol transport mechanism, by transporters in both the yolk sac and placenta, is becoming better understood. This minireview summarizes current insights on maternal-fetal cholesterol transport based on in vitro and in vivo studies. As the prevalence of maternal diseases, such as diabetes, obesity, and the metabolic syndrome that adversely affect maternal cholesterol levels, is now rapidly reaching epidemic proportions, we urgently need to determine the impact of these maternal conditions on the developing human fetus.

Citing Articles

Modeling maternal cholesterol exposure reveals a reduction of neural progenitor proliferation using human cerebral organoids.

Fan P, Wang Y, Lu K, Hong Y, Xu M, Han X Life Med. 2025; 2(2):lnac034.

PMID: 39872117 PMC: 11749704. DOI: 10.1093/lifemedi/lnac034.


Inferring metabolic objectives and trade-offs in single cells during embryogenesis.

Lin D, Zhang L, Zhang J, Chandrasekaran S Cell Syst. 2025; 16(1):101164.

PMID: 39778581 PMC: 11738665. DOI: 10.1016/j.cels.2024.12.005.


Mapping the lipidomic secretome of the early equine embryo.

Lawson E, Pickford R, Aitken R, Gibb Z, Grupen C, Swegen A Front Vet Sci. 2024; 11:1439550.

PMID: 39430383 PMC: 11486720. DOI: 10.3389/fvets.2024.1439550.


Association between maternal cardiometabolic markers and fetal growth in non-complicated pregnancies: a secondary analysis of the PRINCESA cohort.

Omana-Guzman I, Ortiz-Hernandez L, Ancira-Moreno M, Godines-Enriquez M, ONeill M, Vadillo-Ortega F Sci Rep. 2024; 14(1):9096.

PMID: 38643289 PMC: 11032337. DOI: 10.1038/s41598-024-59940-5.


Oncofetal reprogramming in tumor development and progression: novel insights into cancer therapy.

Cao J, Zhang Z, Zhou L, Luo M, Li L, Li B MedComm (2020). 2023; 4(6):e427.

PMID: 38045829 PMC: 10693315. DOI: 10.1002/mco2.427.